Purchase this article with an account.
Emily Dosmar, Jennifer J Kang-Mieler, William F Mieler; Controlled vancomycin release from biodegradable nanoparticles. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3986.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study was to investigate the use of poly (lactic-co-glycolic acid) (PLGA) based nanoparticles to deliver prophylactic vancomycin (VAN) for two weeks following ocular surgery.
VAN was encapsulated in hydrolytically degradable acid terminated PLGA based nanoparticles. Nanoparticles were synthesized using a double emulsion processes. Lactide:glycolide (PL:GA) ratios and molecular weight were varied to assess the release characteristics of the nanoparticles. VAN release profiles were conducted at 37°C; at predetermined intervals, samples were analyzed via light spectroscopy using a NanoDrop™ 2000/2000C (280nm, E1% 40) to quantify VAN concentration.
Nanoparticle encapsulation efficiency was 26 ± 5% for all protocols. PL:GA ratio and molecular weight (MW) did not appear to affect the initial burst of drug (drug release within the first 24 hours) from the nanoparticles (207 ± 3 mg/ml and 204 ± 3 mg/ml for PLGA 75:25; MW 4,000-15,000 and PLGA 50:50; MW 7,000-17,000, respectively). Nanoparticles synthesized from a combination of two different PL:GA ratios (equal parts 75:25 and 50:50) demonstrated a higher initial burst of drug (605 ± 1 mg/ml). Following the initial burst, nanoparticles released a steady level of 8 ± 5 mg/ml, 11 ± 5 mg/ml, and 3 ± 3 mg/ml for PLGA 75:25, PLGA 50:50, and 50% combined nanoparticles, respectively. PL:GA ratio and molecular weight did not demonstrate a strong influence on early release characteristics. The combined polymer system released the smallest amount following a large initial burst.
This study demonstrated that while a combined polymer system does not improve release characteristics, nanoparticles fabricated from PLGA 75:25 or PLGA 50:50 may have promise for application as a vehicle for short term, prophylactic antibiotic ocular drug delivery.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only